Valuation : Aradigm Corporation

Market Cap 4.89M 4.2M 3.96M 3.61M 6.76M 461M 6.78M 46.74M 18.14M 237M 18.34M 17.94M 762M P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 12.8M 11.01M 10.36M 9.47M 17.71M 1.21B 17.75M 122M 47.51M 620M 48.06M 47.01M 2B EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 702K
-1.09%-2.77%-1.68%+13.85% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
+0.53%-1.36%+16.87%+46.82% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.21%-0.94%+12.42%+31.61% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.70%+0.53%+73.88%+110.16% 30.55B
Weighted average by Cap. -0.78%+0.11%+89.35%+128.87%

Financials

2016 2017
Net sales 195K 168K 158K 144K 270K 18.41M 271K 1.87M 724K 9.45M 732K 716K 30.43M 14.46M 12.45M 11.71M 10.7M 20.01M 1.37B 20.07M 138M 53.7M 701M 54.32M 53.13M 2.26B
Net income -32.94M -28.34M -26.67M -24.36M -45.57M -3.11B -45.69M -315M -122M -1.6B -124M -121M -5.14B -10.7M -9.21M -8.67M -7.92M -14.81M -1.01B -14.85M -102M -39.74M -519M -40.2M -39.32M -1.67B
Net Debt -9.37M -8.06M -7.59M -6.93M -12.97M -885M -13M -89.66M -34.79M -454M -35.19M -34.43M -1.46B 7.91M 6.81M 6.41M 5.85M 10.95M 747M 10.98M 75.7M 29.38M 383M 29.71M 29.07M 1.23B
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!